Year-to-date money raised in public, private and other financings of biopharma companies.

Follow-ons completed by biopharma companies, including: Adma, Adverum, Agile, Appili, Applied Genetic Technologies, Atyr, Avrobio, Axovant Gene, Bioxcel, Briacell, Can-Fite, Catalyst, Collegium, Deciphera, Diamedica, Eyepoint, Fortress, Intec, Kezar Life Sciences, Miragen, Moderna, Novan, Oramed, PDS, Phio, Polarityte, Rapt, Rockwell Medical, Salarius, Seelos, Theravance, Tonix, Xeris, Ziopharm, Zosano.

Private placements and other private financings of public biopharma companies, including: Acerus, Adamis, Aeterna Zentaris, Agile, Algernon, Alimera, Aptorum, Arch, Armata, Avadel, Biomerica, Cidara, Cocrystal, Collegium, Collplant, Cortexyme, CTI, Curis, Daré, Enlivex, E-therapeutics, Genmab, Genprex, Hemostemix, Kali-Extracts, Lidds, Lipocine, Mereo, Moleculin, Navidea, Novacyt, Orphazyme, Outlook, Phio, Promis, Redhill, Redx, Revance, Revive, Spero, Syndax, Syros, Valneva, Vaxil, Xortx, Zelira.

Venture capital and other private financings of private biopharma companies, including: Aivita, Alladapt, Alx Oncology, Aurora Science, Azafaros, Canbridge, Ikarovec, Inotrem, Kahr Medical, Kaipharm, Maat Pharma, Neotx, Novelty Nobility, Omass, Oncodna, Pentixapharm, Pinpoint, Sonoma, Spruce Biosciences, Valo, Volastra.

Triggered milestone payments disclosed by biopharma companies, including:Aduro, Alvogen Korea, Arecor, Basilea, Bristol-Myers Squibb, Cytomx, Eurofarma Laboratórios, Merck & Co., Molecular Templates, Oncodesign, Pfizer, Servier, Summit, Takeda, Vivus.

The top 10 biopharma stock gainers and losers for the week.